Company intelligence / Profile preview

Pinnacle In Vitro Diagnostics

Ownership: Private
Development stage: Other

Overview

Pinnacle In Vitro Diagnostics (Pinnacle IVD Corporation) is a U.S.-based manufacturer of point-of-care in vitro diagnostic tests, historically a leader in colon cancer screening and other IVDs, and during the COVID-19 pandemic it commercially launched the CovID RAD Rapid Antigen Detection Test and the CovID NEO IgG/IgM antibody rapid test as 15‑minute lateral flow assays for SARS‑CoV‑2 that can be performed at the point of care without laboratory equipment.[7][9][12]

Therapeutic areas: OncologyGastroenterologyInfectious Diseases
Modalities: DeviceDiagnostic testIn vitro diagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

Aytu BioScience (now Aytu BioPharma) – global distribution agreement for the CovID RAD Rapid Antigen Detection Test.[7][9]

Beyond the preview

Go deeper on Pinnacle In Vitro Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinnacle In Vitro Diagnostics.

Explore the full profile